HC Wainwright & Co. assumes coverage of Autolus Therapeutics at Buy, sets price target at $10

HC Wainwright initiated coverage of Autolus Therapeutics with a Buy rating and $10 price target, implying 557.9% upside from $1.52 close on Oct 30.

Original reporting
Published Nov 2, 2026, 11:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. assumes coverage of Autolus Therapeutics at Buy, sets price target at $10 — source image
Decision brief

The 30-second read

$AUTLBullishMed
01

Why it matters

The new coverage and price target could trigger short‑term buying, especially from retail and small‑cap focused funds.

02

Market read

Primary micro‑cap news; may affect AUTL and biotech sentiment but limited broader market impact.

03

What to watch

Potential regulatory setbacks or clinical trial delays could negate the upside.

Relevance 6/10Novelty 7/10Timing: immediate today

Background

Autolus Therapeutics (NASDAQ:AUTL) is a clinical‑stage immunotherapy company focused on engineered T‑cell therapies.

Company-level read

Ticker impact

$AUTLBullishHigh confidence
Context

HC Wainwright initiates coverage of Autolus Therapeutics with a Buy rating and a $10 price target, implying a 558% upside from the recent close.

Expected impact

upward pressure as investors price in the new target

Evidence & confidence

Coverage initiation and a large upside estimate are fresh, material signals for a micro‑cap biotech.

Market effects

May lift sentiment in the biotech sector as analysts seek undervalued targets.

Limited to US biotech investors; negligible broader market effect.

Low

Counterpoint

The $10 target may be overly optimistic given Autolus' early‑stage pipeline and valuation volatility.

Key entities

  • HC Wainwright & Co.

    Equity research firm that initiated coverage with a Buy rating.

  • Autolus Therapeutics

    Biotech firm developing T‑cell therapies, listed on NASDAQ.

Related articles

$AUTLHighAI 8/10

Autolus (AUTL) Q3 2026 Earnings Call Transcript

Autolus (AUTL) reported Q3 2026 earnings, raising full-year revenue guidance to $150M+. Net revenue grew 95% YoY to $41.2M, with gross margins improving to 57%. The company expects to fund operations into Q2 2028. AUCATZYL's performance and manufacturing efficiency drove results. Clinical trials for AUCATZYL, AUTO8, and other pipeline products are progressing, with data presentations planned for upcoming conferences.

$AUTLHigh

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL®…

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026

$AUTLMedAI 8/10

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus Therapeutics (AUTL) reported Q2 2026 revenue of $45.7M, up 119% YoY, driven by AUCATZYL sales. The company raised full-year guidance to $140M-$150M and secured a $250M credit facility. Despite improved margins, Autolus posted a $39.1M net loss and cash decreased to $201.6M. AUCATZYL carries significant safety warnings, and $150M of financing is tied to revenue milestones.